Navamedic (NAVA)

[TekBot]

NAVAMEDIC ASA: RESOLUTION TO INCREASE THE SHARE CAPITAL IN CONNECTION WITH THE SUBSEQUENT OFFERING AND TERMS OF THE SUBSEQUENT OFFERING

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Reference is made to the stock exchange announcement from Navamedic ASA (“Navamedic” or the “Company”) published on 18 February 2020 regarding the successfully completed private placement raising approximately NOK 50 million in gross proceeds by issuance of 2,630,000 new shares consisting of two tranches of 1,186,767 (“Tranche 1”) and 1,443,233 (“Tranche 2”), respectively (the “Private Placement”), as well as the stock exchange announcement published on the same day with key information about the contemplated subsequent offering of up to 526,000 additional new shares, each with a nominal value of NOK 0.74, at a subscription price of NOK 19 per share (the “Subsequent Offering”).
…

Vis børsmeldingen

Reference is further made to the extraordinary general meeting in the Company held on 11 March 2020, amongst other resolving to grant an authorisation to the Company’s board of directors to carry out the Subsequent Offering by increasing the share capital with up to NOK 389,240 by issuance of up to 526,000 new shares, each with a nominal value of NOK 0.74. Pursuant to the authorisation, the Company’s board of directors has today resolved to increase the share capital by minimum NOK 0.74 and maximum NOK 389,240, by issuance of minimum 1 and maximum 526,000 new shares (the “Offer Shares”) at a subscription price of NOK 19.00 in connection with the Subsequent Offering.

Key terms of the Subsequent Offering:

• The Company’s existing shareholders as of 18 February 2020 (as registered in the Norwegian Central Depository (VPS) on 20 February 2020) who (i) were not allocated shares in the Private Placement, and (ii) who are not resident in a jurisdiction where such offering would be unlawful, or for jurisdictions other than Norway, would require any filing, registration or similar action (the “Eligible Shareholders”), will be granted non-transferable subscription rights that give a preferential right to subscribe for and be allocated Offer Shares. The shareholders’ preferential right to subscribe for the Offer Shares will thus be deviated from.

• Each Eligible Shareholder will receive 0.0625 non-transferable subscription rights for each share registered on such Eligible Shareholder in the Company’s shareholder register in the VPS as of 20 February 2020 (the “Subscription Rights”). The number of Subscription Rights granted to each Eligible Shareholder will be rounded down to the nearest whole Subscription Right. Each Subscription Right will, subject to the applicable securities laws, give the right to subscribe for and be allocated one (1) new Offer Share. Over-subscription is permitted. Subscription without Subscription Rights is not permitted.

• The subscription price in the Subsequent Offering is NOK 19 per Offer Share, being the same as the subscription price in the Private Placement (the “Subscription Price”).

• Subject to the approval of a prospectus (comprising a registration document, a securities note and a summary, jointly the “Prospectus”) by the Financial Supervisory Authority of Norway (the “NFSA”) on 27 May 2020, the subscription period in the Subsequent Offering will commence at 09:00 hours (CET) on 28 May 2020 and expire at 16:30 hours (CET) on 11 June 2020. If the Prospectus is not approved in time to uphold this subscription period, the subscription period shall commence on the first trading day on the Oslo Stock Exchange following such approval by the NFSA and expire at 16:30 hours (CET) two weeks thereafter. The subscription period may not be shortened, but the board of directors may extend the subscription period if this is required by law due to the publication of a supplement prospectus.

• The Subscription Rights are expected to have an economic value if the Company’s shares trade above the Subscription Price during the Subscription Period.

• The Subscription Rights must be used to subscribe for Offer Shares before the expiry of the Subscription Period on 11 June 2020 at 16:30 hours (CET). Subscription Rights that are not exercised before 16:30 hours (CET) on 11 June 2020 will have no value and will lapse without compensation to the holder.

• Allocation of the Offer Shares is expected to take place on or about 12 June 2020.

• The payment for the Offer Shares allocated to a subscriber falls due on or about 16 June 2020.

Additional information on the Subsequent Offering and instructions regarding the procedures for subscription will be included in the Prospectus.

Subject to timely payment of the entire subscription amount in the Subsequent Offering and no extension of the Subscription Period, the Company expects that the share capital increase pertaining to the Subsequent Offering will be registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret) on or about 23 June 2020 and that the Offer Shares will be delivered to the VPS accounts of the subscribers to whom they are allocated on or about 23 June 2020.

SpareBank 1 Markets AS is acting as manager in the Subsequent Offering.

Advokatfirmaet Thommessen AS is acting as legal advisor to the Company in connection with the Subsequent Offering.

For further information about the Company, please contact:
Kathrine G. Andreassen, CEO, Navamedic,
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic,
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

For information about the Subsequent Offering please contact the manager:
SpareBank 1 Market AS, tel +47 24 14 74 70

About Navamedic
Navamedic ASA is a preferred, full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com

IMPORTANT INFORMATION
These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities of the Company in the United States or any other jurisdiction. The securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities of the Company have not been, and will not be, registered under the U.S. Securities Act. Any sale in the United States of the securities mentioned in this communication will be made solely to “qualified institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No public offering of the securities will be made in the United States.

In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression “Prospectus Regulation” means Regulation (EU) 2017/1129 (together with any applicable implementing measures in any Member State).

In the United Kingdom, this communication is only addressed to and is only directed at Qualified Investors who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as “Relevant Persons”). These materials are directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this announcement relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.

Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “anticipate”, “believe”, “continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The Manager is acting exclusively for the Company and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, or for advice in relation to the contents of this announcement or any of the matters referred to herein.

Neither the Manager nor any of its respective affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. Neither the
Manager nor any of its respective affiliates accepts any liability arising from the use of this announcement.

Any offering of the securities referred to in this announcement will be made by means of a prospectus. This announcement is an advertisement and is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on prospectuses to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (as amended) as implemented in any Member State. Investors should not subscribe for any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus, if a prospectus is published. Copies of any such prospectus will, following publication, be available from the Company’s registered office and, subject to certain exceptions, on the websites of SpareBank 1 Markets (https://www.sb1markets.no/).

Each of the Company, the Manager and their respective affiliates expressly disclaims any obligation or undertaking to update, review or revise any statement contained in this announcement whether as a result of new information, future developments or otherwise.

The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

NAVAMEDIC ASA: APPROVED PROSPECTUS, LISTING OF PRIVATE PLACEMENT SHARES AND COMMENCEMENT OF SUBSCRIPTION PERIOD IN THE SUBSEQUENT OFFERING

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Reference is made to the stock exchange announcement from Navamedic ASA (“Navamedic” or the “Company”) published on 18 February 2020 regarding the successfully completed private placement raising approximately NOK 50 million in gross proceeds by issuance of 2,630,000 new shares consisting of two tranches of 1,186,767 shares (“Tranche 1”) and 1,443,233 shares (“Tranche 2”), respectively (the “Private Placement”), as well as the stock exchange announcement published on 25 May 2020 regarding the resolution by the Company’s board of directors to increase the Company’s share capital by minimum NOK 0.74 and maximum NOK 389,240, by issuance of minimum 1 and maximum 526,000 new shares, each with a nominal value of NOK 0.74, at a subscription price of NOK 19.00 per share (the “Offer Shares”) in connection with the subsequent offering (the “Subsequent Offering”).
…

Vis børsmeldingen

Approved prospectus and publication:

The Financial Supervisory Authority of Norway has today, on 27 May 2020, approved a prospectus prepared by the Company, comprising a registration document, a securities note and a summary (jointly, the “Prospectus”) which has been prepared in connection with (i) the listing on Oslo Axess of the 1,443,233 new shares in the Company pertaining to Tranche 2 of the Private Placement and (ii) the Subsequent Offering.

Subject to certain limitations in applicable local securities law, the Prospectus together with the subscription form for the Subsequent Offering will be made available at the website of SpareBank 1 Markets AS (www.sb1markets.no) no later than 08:00 (CET) tomorrow, on 28 May 2020. Printed versions of the Prospectus including the subscription form may also be obtained by contacting SpareBank 1 Markets AS (tel +47 24 14 74 70) or the Company.

Listing of the new shares pertaining to Tranche 2 of the Private Placement:

The 1,443,233 new shares in Tranche 2 which were issued in connection with the Private Placement have been registered at a separate ISIN pending publication of the Prospectus. Following the publication of the Prospectus, these shares will be transferred to the same ISIN as the other shares in the Company (ISIN NO 0010205966) and will thereby be listed on Oslo Axess.

Commencement of the subscription period in the Subsequent Offering:

The subscription period in the Subsequent Offering will commence tomorrow, on 28 May 2020 at 09:00 (CET) and will expire on 11 June 2020 at 16:30 (CET). For further information regarding the Subsequent Offering, please see the Company’s stock exchange announcement from 25 May 2020 containing key information about the Subsequent Offering. Additional information regarding the Subsequent Offering and instructions regarding the procedures for subscription of the Offer Shares is included in the Prospectus. Eligible shareholders will also receive a letter from the Manager (as defined below) with further details on the number of subscription rights granted to such eligible shareholder.

SpareBank 1 Markets AS is acting as manager in the Subsequent Offering (the “Manager”). Advokatfirmaet Thommessen AS is acting as legal advisor to the Company in connection with the Subsequent Offering.

For further information about the Company, please contact:
Kathrine G. Andreassen, CEO, Navamedic,
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic,
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

For information about the Subsequent Offering please contact the manager:
SpareBank 1 Market AS, tel +47 24 14 74 70

About Navamedic
Navamedic ASA is a preferred, full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com

IMPORTANT INFORMATION
These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities of the Company in the United States or any other jurisdiction. The securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities of the Company have not been, and will not be, registered under the U.S. Securities Act. Any sale in the United States of the securities mentioned in this communication will be made solely to “qualified institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No public offering of the securities will be made in the United States.

In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression “Prospectus Regulation” means Regulation (EU) 2017/1129 (together with any applicable implementing measures in any Member State).

In the United Kingdom, this communication is only addressed to and is only directed at Qualified Investors who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as “Relevant Persons”). These materials are directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this announcement relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.

Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “anticipate”, “believe”, “continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The Manager is acting exclusively for the Company and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, or for advice in relation to the contents of this announcement or any of the matters referred to herein.

Neither the Manager nor any of its respective affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein.
This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. Neither the Manager nor any of its respective affiliates accepts any liability arising from the use of this announcement.

Any offering of the securities referred to in this announcement will be made by means of a prospectus. This announcement is an advertisement and is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on prospectuses to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (as amended) as implemented in any Member State. Investors should not subscribe for any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus, if a prospectus is published. Copies of any such prospectus will, following publication, be available from the Company’s registered office and, subject to certain exceptions, on the websites of SpareBank 1 Markets (https://www.sb1markets.no/).

Each of the Company, the Manager and their respective affiliates expressly disclaims any obligation or undertaking to update, review or revise any statement contained in this announcement whether as a result of new information, future developments or otherwise.

The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

This information is published in accordance with the requirements of the Oslo Stock Exchange’s Continuing Obligations.

Kilde

[Savepig]

[TekBot]

Navamedic ASA: Annual General Meeting held

Navamedic ASA has today, June 3[rd] 2020, held the Annual General Meeting. All
resolutions were made in accordance with the board’s/nomination committee’s
proposals. The minutes from the general meeting is attached hereto and will also
…

Vis børsmeldingen

be available at www.navamedic.com.

For further information please contact: Lars Hjarrand, CFO.

E-mail: lars.hjarrand@navamedic.com Phone +47 917 62 842

This information is subject of the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

NAVAMEDIC ASA: RESOLUTION TO INCREASE THE SHARE CAPITAL IN CONNECTION WITH EXERCISE OF EMPLOYEE OPTIONS

Oslo, 10 June 2020: The board of directors of Navamedic ASA (the “Company”),
has on 9 June 2020, in accordance with the authorisation granted to it by the
general meeting on 3 June 2020, resolved to increase the Company’s share capital
…

Vis børsmeldingen

by minimum NOK 0.74 and maximum NOK 34,687.50 by issuance of minimum 1 and
maximum 46,875 new shares, each with a nominal value of NOK 0.74, in order to
facilitate the completion of an exercise period for the 46,875 vested share
options under the Company’s 2018 option program.

The exercise period shall not commence prior to the completion of the ongoing
subsequent offering in the Company (which will be deemed completed upon the
delivery of the offer shares to the investors) and shall expire no later than
16.30 hours (CET) on 3 July 2020.

The share capital increase will be registered with the Norwegian Register of
Business Enterprises (Nw. Foretaksregisteret) as soon as practically possible
after the exact amount of the capital increase has been determined.

For further information, please contact:

Lars Hjarrand, CFO, Navamedic,
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a preferred, full-service provider of high-quality healthcare
products to hospitals and pharmacies. Navamedic meets the specific medical
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please visit
www.navamedic.com

This information is subject of the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

NAVAMEDIC ASA: LAST DAY OF SUBSCRIPTION PERIOD IN THE SUBSEQUENT OFFERING

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Reference is made to the stock exchange announcement from Navamedic ASA (the
“Company”) published on 27 May 2020 regarding the commencement of a subsequent
offering of up to 526,000 new shares in the Company (the “Offer Shares”) at a
subscription price of NOK 19.00 per share (the “Subsequent Offering”).

The subscription period in the Subsequent Offering will expire today, on 11 June
2020 at 16:30 hours (CET). Correctly completed subscription forms must be
received by the manager in the Subsequent Offering, SpareBank 1 Markets AS (the
“Manager”), or, in the case of online subscriptions, be registered, within this
deadline. Subscription rights that are not used to subscribe for Offer Shares
within this deadline will have no value and will lapse without compensation to
the holder.

For more information, please see the prospectus prepared by the Company dated 27
May 2020, comprising a registration document, a securities note and a summary
(jointly, the “Prospectus”). The Prospectus, including the subscription form, is
available at www.sb1markets.com.

SpareBank 1 Markets AS is acting as manager in the Subsequent Offering.
Advokatfirmaet Thommessen AS is acting as legal advisor to the Company in
connection with the Subsequent Offering.

For further information about the Company, please contact:

Kathrine G. Andreassen, CEO, Navamedic,
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic,
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

For information about the Subsequent Offering please contact the manager:
SpareBank 1 Market AS, tel +47 24 14 74 70

About Navamedic

Navamedic ASA is a preferred, full-service provider of high-quality healthcare
products to hospitals and pharmacies. Navamedic meets the specific medical needs
of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please visit
www.navamedic.com

IMPORTANT INFORMATION

These materials do not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State. The expression “Prospectus
Regulation” means Regulation (EU) 2017/1129 (together with any applicable
implementing measures in any Member State).

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). These materials are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Manager is acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Manager nor any of its respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the Manager
nor any of its respective affiliates accepts any liability arising from the use
of this announcement.

The offering of the securities referred to in this announcement is made by means
of the Prospectus. This announcement is an advertisement and is not a prospectus
for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of
the Council of 14 June 2017 on prospectuses to be published when securities are
offered to the public or admitted to trading on a regulated market, and
repealing Directive 2003/71/EC (as amended) as implemented in any Member State.
Investors should not subscribe for any securities referred to in this
announcement except on the basis of information contained in the Prospectus.
Copies of the Prospectus are available from the Company’s registered office and,
subject to certain exceptions, on the website of SpareBank 1 Markets
(https://www.sb1markets.no/).

Each of the Company, the Manager and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

Kilde

[TekBot]

NAVAMEDIC ASA: PRELIMINARY RESULTS OF THE SUBSEQUENT OFFERING

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Reference is made to the stock exchange announcement from Navamedic ASA (the
“Company”) published on 27 May 2020 regarding the commencement of a subsequent
offering of up to 526,000 new shares in the Company (the “Offer Shares”) at a
subscription price of NOK 19.00 per share (the “Subsequent Offering”).

The subscription period in the Subsequent Offering expired today on 11 June 2020
at 16:30 hours (CET).

Preliminary counting indicates that the Company has received subscriptions for
approximately 446,478 Offer Shares in the Subsequent Offering. The preliminary
counting indicates no over-subscriptions have been made.

The final allocation of the Offer Shares in the Subsequent Offering is expected
to take place tomorrow on 12 June 2020 in accordance with the allocation
criteria set out in the prospectus dated 27 May 2020, comprising a registration
document, a securities note and a summary (jointly the “Prospectus”). The final
result of the Subsequent Offering will be published shortly thereafter, and
letters regarding allocation of Offer Shares and the corresponding subscription
amount to be paid by each subscriber, are expected to be distributed on or about
the same day.

The due date for payment of the Offer Shares is expected to be on or about 16
June 2020.

SpareBank 1 Markets AS is acting as manager in the Subsequent Offering.
Advokatfirmaet Thommessen AS is acting as legal advisor to the Company in
connection with the Subsequent Offering.

For further information about the Company, please contact:

Kathrine G. Andreassen, CEO, Navamedic,
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic,
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

For information about the Subsequent Offering please contact the manager:
SpareBank 1 Market AS, tel +47 24 14 74 70

About Navamedic

Navamedic ASA is a preferred, full-service provider of high-quality healthcare
products to hospitals and pharmacies. Navamedic meets the specific medical needs
of patients and consumers by leveraging its highly scalable market access

platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please visit
www.navamedic.com

IMPORTANT INFORMATION

These materials do not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State. The expression “Prospectus
Regulation” means Regulation (EU) 2017/1129 (together with any applicable
implementing measures in any Member State).

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). These materials are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Manager is acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Manager nor any of its respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the Manager
nor any of its respective affiliates accepts any liability arising from the use
of this announcement.

The offering of the securities referred to in this announcement is made by means
of the Prospectus. This announcement is an advertisement and is not a prospectus
for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of
the Council of 14 June 2017 on prospectuses to be published when securities are
offered to the public or admitted to trading on a regulated market, and
repealing Directive 2003/71/EC (as amended) as implemented in any Member State.
Investors should not subscribe for any securities referred to in this
announcement except on the basis of information contained in the Prospectus.
Copies of the Prospectus are available from the Company’s registered office and,
subject to certain exceptions, on the website of SpareBank 1 Markets
(https://www.sb1markets.no/).

Each of the Company, the Manager and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

This information is subject of the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Savepig]

Nesten fylt opp, bra det

[TekBot]

NAVAMEDIC ASA: GRANT OF OPTIONS TO EMPLOYEES

Oslo, 11 June 2020: On the basis of Navamedic ASA’s (the “Company”) annual
general meeting’s resolution on 3 June 2020 to authorise the board of directors
of the Company (the “Board”) to issue new option shares to the executive
…

Vis børsmeldingen

management and other leaders in the group under the Company’s long-term
incentive program, the Board has resolved to issue 480.000 new share options to
the Company’s executive management.

Each option will upon exercise give the option holder the right to acquire one
share in the Company. The options are granted without consideration. Pursuant to
the vesting schedule and certain other terms and conditions of the grant, 1/3 of
the share options will vest on the first anniversary of the day of grant, 1/3 of
the share options will vest on the second anniversary of the day of grant, and
the remaining 1/3 of the share options will vest on the third anniversary of the
day of grant.

The exercise price of each option is NOK 19.00. Options that are not exercised
within 12 months after the third anniversary of the date of grant, will subject
to certain limitations, lapse without any compensation to the holder.

The following primary insiders of the Company have received options on the terms
described above:

• Kathrine Gamborg Andreassen, CEO in the Company, has been granted 105.000
  options. Following the grant Kathrine Gamborg Andreassen, with her related
  parties own 541.668 shares and 230.000 options in the Company.

• Lars Hjarrand, CFO in the Company, has been granted 75.000 options. Following
  the grant Lars Hjarrand, with his related parties own 185.882 shares and 150.000
  options in the Company.

• Ole Henrik Eriksen, COO in the Company, has been granted 75.000 options.
  Following the grant Ole Henrik Eriksen, with his related parties own 491.666
  shares and 75.000 options in the Company.

• Astrid T. Bratvedt, CSO in the Company, has been granted 75.000 options.
  Following the grant Astrid T. Bratvedt, with her related parties own 493.666
  shares and 75.000 options in the Company.

• Alexander Lidmejer, Commercial Dir Specialty Pharma in the Company, has been
  granted 75.000 options. Following the grant Alexander Lidmejer, with his related
  parties own 2.400 shares and 75.000 options in the Company.

For further information please contact: Lars Hjarrand, CFO.

E-mail: lars.hjarrand@navamedic.com Phone +47 917 62 842

This information is subject of the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

NAVAMEDIC ASA: FINAL RESULT OF THE SUBSEQUENT OFFERING

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Reference is made to the stock exchange announcement from Navamedic ASA (the
“Company”) published yesterday, on 11 June 2020, regarding the preliminary
results in the subsequent offering of up to 526,000 new shares in the Company
(the “Offer Shares”) at a subscription price of NOK 19.00 per share (the
“Subsequent Offering”).

The subscription period in the Subsequent Offering expired yesterday, on 11 June
2020, at 16:30 hours (CET).

The final allocation of the Offer Shares in the Subsequent Offering has now been
completed based on the allocation criteria set out in the Company’s prospectus
dated 27 May 2020, comprising a registration document, a securities note and a
summary (the “Prospectus”).

Upon the expiry of the subscription period and following the final review of the
subscriptions received in the Subsequent Offering, the Company had received
valid subscriptions for a total of 347,337 Offer Shares, of which 239,097 Offer
Shares were allocated based on subscription rights, and 108,240 Offer Shares
were allocated to subscribers who had over-subscribed in the Subsequent
Offering. The reduced number of subscriptions received from what was indicated
in the stock exchange announcement yesterday informing about the preliminary
result of the Subsequent Offering, is due to the fact that certain subscriptions
were made without subscription rights, which is not permitted pursuant to the
terms of the Subsequent Offering.

The board of directors of the Company has allocated a total of 347,337 Offer
Shares to applicants with subscription rights. All subscribers having exercised
valid subscriptions have received full allocation. Thus, 347,337 Offer Shares
will be issued in the Subsequent Offering.

Notifications of allocated Offer Shares in the Subsequent Offering and the
corresponding subscription amount to be paid by each subscriber will be set out
in a separate letter to each subscriber to whom Offer Shares have been allotted.
The allocation letters are expected to be distributed today. The due date for
payment of the Offer Shares is 16 June 2020.

The share capital increase pertaining to the Subsequent Offering is expected to
be registered with the Norwegian Register of Business Enterprises on or about 23
June 2020 and the Offer Shares will be delivered to the VPS accounts of the
subscribers to whom they are allocated and listed on Oslo Børs on or about the
same day.

SpareBank 1 Markets AS is acting as manager in the Subsequent Offering (the
“Manager”). Advokatfirmaet Thommessen AS is acting as legal advisor to the
Company in connection with the Subsequent Offering.

The following primary insiders of the Company have exercised their subscription
rights and been allocated Offer Shares in the Subsequent Offering:

• Ole Henrik Eriksen, COO in the Company, has through his related party
  Leikerane AS, been allocated 8,334 Offer Shares. Following the allocation Ole
  Henrik Eriksen, with his related parties own 500,000 shares and 75,000 options
  in the Company.

• Astrid T. Bratvedt, CSO in the Company, has through her related party
  Tranbergkollen Invest AS been allocated 33,334 Offer Shares. Following the
  grant Astrid T. Bratvedt, with her related parties own 527,000 shares and 75,000
  options in the Company.

For further information about the Company, please contact:

Kathrine G. Andreassen, CEO, Navamedic,
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic,
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

For information about the Subsequent Offering please contact the manager:
SpareBank 1 Market AS, tel +47 24 14 74 70

About Navamedic

Navamedic ASA is a preferred, full-service provider of high-quality healthcare
products to hospitals and pharmacies. Navamedic meets the specific medical needs
of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please visit
www.navamedic.com

IMPORTANT INFORMATION

These materials do not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State. The expression “Prospectus
Regulation” means Regulation (EU) 2017/1129 (together with any applicable
implementing measures in any Member State).

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). These materials are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Manager is acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Manager nor any of its respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the Manager
nor any of its respective affiliates accepts any liability arising from the use
of this announcement.

The offering of the securities referred to in this announcement is made by means
of the Prospectus. This announcement is an advertisement and is not a prospectus
for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of
the Council of 14 June 2017 on prospectuses to be published when securities are
offered to the public or admitted to trading on a regulated market, and
repealing Directive 2003/71/EC (as amended) as implemented in any Member State.
Investors should not subscribe for any securities referred to in this
announcement except on the basis of information contained in the Prospectus.
Copies of the Prospectus are available from the Company’s registered office and,
subject to certain exceptions, on the website of SpareBank 1 Markets
(https://www.sb1markets.no/).

Each of the Company, the Manager and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

This information is subject of the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Savepig]

Var litt forvirrende innlegg her, så bare slettet så det er åpenbart at det er emien til nava vi diskuterer.

@Quadruple kjenner vel caset best, kommentarer?

[TekBot]

NAVAMEDIC ASA: REGISTRATION OF SHARE CAPITAL INCREASE

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Reference is made to the stock exchange announcement from Navamedic ASA (the
“Company”) published on 12 June 2020 regarding the final result of the
subsequent offering where 347,337 new shares (the “New Shares”) were allocated
at a subscription price of NOK 19.00 per share (the “Subsequent Offering”).

The share capital increase pertaining to the Subsequent Offering has now been
registered with the Norwegian Register of Business Enterprises (Nw.
Foretaksregisteret). The new share capital of the Company is NOK 11,188,807.40
divided into 15,120,010 shares, each with a par value of NOK 0.74.

Following the registration of the New Shares in the Norwegian Central Securities
Depository (the VPS), which is expected to take place today, the New Shares will
be listed on Oslo Børs and delivered to the subscribers allocated shares in the
Subsequent Offering.

For further information about the Company, please contact:

Kathrine G. Andreassen, CEO, Navamedic,
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic,
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a preferred, full-service provider of high-quality healthcare
products to hospitals and pharmacies. Navamedic meets the specific medical needs
of patients and consumers by leveraging its highly scalable market access

platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please visit
www.navamedic.com

IMPORTANT INFORMATION

These materials do not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State. The expression “Prospectus
Regulation” means Regulation (EU) 2017/1129 (together with any applicable
implementing measures in any Member State).

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). These materials are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Manager is acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Manager nor any of its respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the Manager
nor any of its respective affiliates accepts any liability arising from the use
of this announcement.

The offering of the securities referred to in this announcement is made by means
of the Company’s prospectus dated 27 May 2020, comprising a registration
document, a securities note and a summary (jointly, the “Prospectus”). This
announcement is an advertisement and is not a prospectus for the purposes of
Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14
June 2017 on prospectuses to be published when securities are offered to the
public or admitted to trading on a regulated market, and repealing Directive
2003/71/EC (as amended) as implemented in any Member State. Investors should not
subscribe for any securities referred to in this announcement except on the
basis of information contained in the Prospectus. Copies of the Prospectus are
available from the Company’s registered office and, subject to certain
exceptions, on the Company’s website (https://navamedic.com/investors/financial
-results/prospectus-2/).

Each of the Company, the Manager and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

This information is published in accordance with the requirements of the Oslo
Stock Exchange’s Continuing Obligations.

Kilde

[TekBot]

Navamedic ASA – Registration of share capital increase

Oslo, 8 July 2020: Reference is made to Navamedic ASA’s (the “Company”) stock exchange announcement published on 10 June 2020 regarding the board of directors’ resolution to increase the Company’s share capital in connection with the completion of an exercise period for vested shares under the Company’s 2018 option program.

The share capital increase pertaining to the exercise period has now been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The new share capital of the Company is NOK 11,223,494.90, divided into 15,166,885 shares, each with a par value of NOK 0.74.
…

Vis børsmeldingen

Following the registration of the new shares in the Norwegian Central Securities Depository (the VPS), which is expected to take place today, on 8 July 2020, the new shares will be delivered to the subscribers and listed on the Oslo Stock Exchange.

For further information, please contact:
Lars Hjarrand, CFO, Navamedic,
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

About Navamedic
Navamedic ASA is a preferred, full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com

This information is published pursuant to the continuing obligations of the Oslo Stock Exchange.

Kilde

[TekBot]

Navamedic ASA: Update on the acquisition of marketing authorisations for antibiotics in the Nordics

Reference is made to the announcement by Navamedic ASA (OSE: NAVA) on 7 February 2020 about the acquisition of a series of antibiotics for hospital use in the Nordic region from ACS Dobfar (Italy) and its subsidiary InfoRLife (Switzerland). As communicated in the announcement, the plan was to close the transaction by the end of June 2020 but due to the COVID-19 situation the finalization of the transaction has been somewhat delayed. The current plan is to close the transaction by end July/early August 2020, followed by a stock exchange announcement.

For further information, please contact:
…

Vis børsmeldingen

Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

About Navamedic
Navamedic ASA is a preferred, full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com

Kilde

[TekBot]

Navamedic ASA completed the acquisition of marketing authorisations for antibiotics in the Nordics

Oslo, 4 August 2020 - Navamedic ASA (“Navamedic”, OSE: NAVA), today announces it
has completed the transaction with ACS Dobfar and InfoRLife for the acquisition
of marketing authorisations for a series of antibiotics for hospital use in the
…

Vis børsmeldingen

Nordic region. Navamedic acquires the marketing authorisations for a total
consideration of up to NOK 38 million.

Reference is made to Navamedic’s announcement on 7 February 2020 about the
acquisition of a series of antibiotics for hospital use in the Nordic region
from ACS Dobfar and its subsidiary InfoRLife. The transaction is now completed,
representing an important step in Navamedic’s growth strategy.

“Navamedic is committed to increasing ownership to assets such as marketing
authorisations, and we are pleased to announce the completion of this
transaction and the beginning of a close collaboration with a solid European
supplier. Antibiotics is an important therapeutic area close to our core
competence. The acquisition is strengthening Navamedic’s hospital offering with
important products and also positioning the company for the addition of more
prescription drugs as we will build systems relevant for a broader product
range,” says Kathrine Gamborg Andreassen, CEO of Navamedic.

The transaction is made with ACS Dobfar S.p.a, an Italian chemical
-pharmaceutical company, and its Swiss subsidiary InfoRLife SA, a pharmaceutical
company developing, registrering and producing ready-to-use medicines. Navamedic
acquires the marketing authorisations for a total consideration of up to NOK 38
million in two tranches. The first tranche of NOK 19 million shall be settled by
issuance of 1,053,775 number of consideration shares in Navamedic at an agreed
subscription price of NOK 18.0304 per share. The subscription price corresponds
to the volume weighted average trading price of the Navamedic shares from 24
January to 6 February 2020, being the 10 last trading days prior to, but not
including, Navamedic’s stock exchange announcement published on 7 February 2020.
The board of directors of Navamedic will issue the consideration shares as soon
as possible following Navamedic becoming registered as the holder of the
material marketing authorisations with the relevant governmental bodies in the
Nordics, which is expected to be completed no later than 31 December 2020,
pursuant to the authorization given to it by the extraordinary general meeting
of the company held on 11 March 2020. The second tranche of up to NOK 19 million
in cash or Navamedic shares upon fulfilment of certain sales volume milestones
for the acquired product portfolio, to be settled no later than 31 January 2024
or 2026.

The antibiotics in the portfolio are designed to be given intravenously to
patients and are currently in regular use in hospitals in all the Nordic
countries with an annual tender-based turnover of approximately NOK 25 million.
As part of the acquisition agreement, the parties have agreed to also enter into
a long-term supply and service agreement including launch of new products in the
future - potentially also outside the Nordic territory.

“Drug shortage is an important issue in the Nordics. By combining Navamedic’s
local expertise with products from a reliable European manufacturer, the
transaction is also important to secure steady supply of key products to Nordic
hospitals. We are looking forward to a close and long-term collaboration with
ACS Dobfar and InfoRLife,” says Gamborg Andreassen.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in the UK and
Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA). For more information, please visit www.navamedic.com

About ACS Dobfar

ACS Dobfar is an Italian, privately held, chemical-pharmaceutical company with
headquarters located outside Milano. In continuous growth, the company is
currently employing more than 3000 people at 23 different facilities in four
continents. Established in 1973, the company is today a fully-integrated
provider of high-quality pharmaceutical intermediates, active pharmaceutical
ingredients (APIs) and finished dosage forms (oral and injectables) and is a
global leader in the antibiotic classes called cephalosporins and carbapenems.
ACS Dobfar products are sold in over 100 countries around the world.

About InfoRLife

Being a subsidiary of ACS Dobfar, InfoRLife is a pharmaceutical company
developing, registering and producing ready-to-use medicines with main facility
in Brusio, Switzerland. The company also controls three subsidiaries located in
Romania, Tunisia and Brazil. InfoRLife is specialized in the manufacture of
medicines in plastic bags using sterile methods and technology with high-quality
content and develops all its new products in its own R&D laboratories. The
company is approved by the USA Food and Drug Administration (FDA) for sales in
the USA, which is its main market.

Kilde

[Quadruple]

Børsverdi under 300 mill. vil kanskje ikke vare så mye lenger nå?

[TekBot]

Navamedic ASA: Invitation to 2020 second quarter presentation

Navamedic ASA invites you to a presentation of the 2020 second quarter figures
on Thursday August 20th at 08.30 CET. Due to the covid-19 situation the
presentation will only be held as a webcast. Participants can view the webcast
…

Vis børsmeldingen

on the Navamedic web site www.navamedic.com/investors/financial-results.

Representatives from the Company will be: CEO Kathrine Gamborg Andreassen and
CFO Lars Hjarrand. For further information, please contact: Lars Hjarrand.
Mobile: +47 917 62 842 E-mail: lars.hjarrand@navamedic.com

There might be availability for a very limited number of people to attend in
person if desired. Should this be of interest you will need to contact CFO Lars
Hjarrand for approval prior to the presentation.

Kilde

[TekBot]

Navamedic ASA: Resultater for andre kvartal og første halvår 2020

Oslo, 20. august 2020 - Navamedic ASA (OSE: NAVA) økte driftsinntektene med 5.5%
i første halvår 2020 sammenlignet med tilsvarende periode i fjor. Selskapet
rapporterte driftsinntekter på NOK 42.1 millioner i andre kvartal 2020, med en
…

Vis børsmeldingen

EBITDA på NOK -2.1 millioner. Navamedic ble påvirket av Covid-19 i kvartalet.
Selskapet fortsatte å styrke sin plattform for vekst i første halvår og gjentar
sin mellomlange- til langsiktige ambisjon om å bli et selskap med NOK 500
millioner i omsetning.

• I første halvår tok vi viktige steg som et rendyrket, nordisk farmaselskap med
  mål om vekst i Nord-Europa. Vi fortsatte å skape vekst for vår eksisterende
  portefølje, har tilføyd nye og relevante produkter i apotek og på sykehus, og
  har lansert produkter i nye land. Vi er glade for å se etterspørselen etter
  produkter som Mysimba® og Alflorex®, begge solide eksempler på attraktiviteten
  til vår portefølje, verdien av vår lokale ekspertise og sterke relasjoner til
  pasienter og kunder, sier Kathrine Gamborg Andreassen, administrerende direktør
  i Navamedic, og fortsetter.

• I halvåret som har gått har vi også jobbet for å håndtere Covid-19-situasjonen
  og minimere effekter på tilbud og etterspørsel som følge av pandemien. I andre
  kvartal opplevde vi noe lavere salg på tvers av produktkategoriene, og
  volatilitet for Imdur®. Vi tok umiddelbart grep for å håndtere situasjonen,
  parallelt med at vi gjennomførte strategisk viktige vekstinvesteringer i
  organisasjonen og plattformen vår. Samlet sett er vi fornøyd med å se at vi har
  fått igjen for innsatsen.

En av de viktigste hendelsene i perioden var kjøpet av markedsføringstillatelser
for en serie av antibiotikaprodukter for bruk på sykehus i Norden. Kjøpet ble
fullført 4. august 2020. Transaksjonen tilfører en anbudsbasert årlig omsetning
på om lag NOK 25 millioner til Navamedics portefølje, og markerer begynnelsen på
et langsiktig samarbeid med en solid, europeisk leverandør. En annen viktig
milepæl var signeringen av en langsiktig, eksklusiv distribusjonsavtale for
ThermaCare® i Norden og det strategisk viktige nederlandske markedet.

• Vi leverer på vår vekststrategi ved å sikre og øke verdi gjennom eierskap til
  produkter og merkevarer, og vi vil lansere produkter i minst ett land i hvert
  lanseringsvindu fremover. Vi fortsetter vekstreisen med en mellomlang- til
  langsiktig ambisjon om å bygge et selskap med NOK 500 millioner i omsetning,
  solide bruttomarginer og underliggende lønnsomhet, sier Gamborg Andreassen.

I andre kvartal 2020 var selskapets driftsinntekter NOK 42.1 millioner (47.2
millioner i andre kvartal 2019). Bruttomarginen var 34.8% (34.4%), og EBITDA
-resultatet var NOK -2.1 millioner (0.9). Resultat før skatt var NOK 0.4
millioner (-0.9) i andre kvartal 2020. I første halvår 2020 var selskapets
driftsinntekter NOK 97.8 millioner (92.7), og EBITDA-resultatet var NOK -1.4
millioner (1.4).

Navamedic avholder en webcast-presentasjon av resultatene for andre kvartal og
første halvår 2020, torsdag 20. august kl 08.30. Grunnet smittevernbestemmelser
knyttet til Covid-19 vil presentasjonen kun avholdes digitalt på
www.navamedic.com/investors/financial-results. Presentasjonen vil holdes av
administrerende direktør Kathrine Gamborg Andreassen og finansdirektør Lars
Hjarrand.

EBITDA og andre alternative resultatmål (APMer) er definert og avstemt med IFRS
-regnskapet som en del av APM-delen på side 19 i vedlagte presentasjon for andre
kvartal og første halvår 2020.

For ytterligere informasjon, vennligst kontakt:

Kathrine Gamborg Andreassen, administrerende direktør, Navamedic
Mobil: +47 951 78 680
E-post: kathrine@navamedic.com

Lars Hjarrand, finansdirektør, Navamedic
Mobil: +47 917 62 842
E-post: lars.hjarrand@navamedic.com

Om Navamedic

Navamedic ASA er et nordisk farmaselskap som leverer høykvalitetsprodukter til
sykehus og apotek. Vår ambisjon er å ivareta pasienters og forbrukeres behov
gjennom dybdekompetanse innen utvalgte kategorier, samt inngående kunnskap om
lokale forhold i hvert marked. Navamedic er til stede i de nordiske landene,
Baltikum og Benelux, og har salgsrepresentasjon i Storbritannia og Hellas.
Navamedic har hovedkontor i Oslo og er notert på Oslo Børs (ticker: NAVA). For
mer informasjon, vennligst besøk www.navamedic.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Navamedic ASA: Q2 and first half 2020 financial results

Oslo, 20 August 2020 - Navamedic ASA (OSE: NAVA) grew revenues by 5.5% in the
first half of 2020 compared to the same period last year. The company reported
revenues of NOK 42.1 million in the second quarter of 2020 with an EBITDA of NOK
…

Vis børsmeldingen

-2.1 million, affected by Covid-19. Navamedic continued to strengthen its growth
platform in the period and reiterates its mid- to long-term ambition of building
a NOK 500 million company.

“In the first half of the year, we took important steps as a pureplay Nordic
pharma company targeting growth in Northern Europe. We continued to grow our
portfolio of existing products, added exciting new products to our pharmacy and
hospital offering, and expanded products to new geographies. We are pleased to
see the uptake of products like Mysimba and Alflorex, both solid examples of our
portfolio’s attractiveness, the value of our local expertise and strong
relationships with customers and patients,” says Kathrine Gamborg Andreassen,
Chief Executive Officer of Navamedic, and continues.

“During the period, we have also worked to manage the Covid-19 situation and
limit effects on supply and demand as a result of the pandemic. In the second
quarter, we experienced some lower sales across our product categories, and
volatility for Imdur®. We took immediate action to handle the situation, in
parallel to making strategically important growth investments in our
organization and platform. We are overall pleased to see that our efforts have
paid off.”

One of the key events in the period was the acquisition of marketing
authorizations for a series of antibiotics for hospital use in the Nordics, in a
transaction which was completed on 4 August 2020. The transaction adds a tender
-based annual turnover of approximately NOK 25 million to Navamedic’s portfolio
and marks the beginning of a long-term collaboration with a solid European
supplier. Another important event was the signing of a long-term exclusive
distribution agreement for ThermaCare® in the Nordics and in the strategically
important Dutch market.

“We execute on our growth strategy by securing and increasing value through
ownership to products and brands, and we will launch products in at least one
country in each launch window going forward. We are continuing our growth
journey with a mid- to long-term ambition of building a NOK 500 million company
with strong gross margins and underlying profitability,” says Gamborg
Andreassen.

Revenues in the second quarter of 2020 were NOK 42.1 million (47.2 million in
the second quarter of 2019). The gross margin was 34.8% (34.4%), while the
EBITDA was NOK -2.1 million (0.9). Result before tax in the second quarter of
2020 was NOK 0.4 million (-0.9). In the first half of 2020, revenues were NOK
97.8 million (92.7), while EBITDA was NOK -1.4 million (1.4).

Navamedic is hosting a webcast presentation of the second quarter and first half
2020 financial results, Thursday 20 August at 08.30 CET. Due to the Covid-19
situation, the presentation will only be held as a live webcast, on
www.navamedic.com/investors/financial-results. Representatives from Navamedic
will be CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand.

EBITDA and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
attached second quarter and first half 2020 presentation on slide 19.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please
visit www.navamedic.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

NAVAMEDIC ASA: Resolution to increase the share capital in connection with exercise of employee options

Oslo, 30 September 2020: The board of directors of Navamedic ASA (the
“Company”), has today, on 30 September 2020, pursuant the authorisation granted
to it by the general meeting on 3 June 2020, resolved to increase the Company’s
…

Vis børsmeldingen

share capital by NOK 92,500 by issuance of 125,000 new shares, each with a
nominal value of NOK 0.74, in order to facilitate today’s exercise of 125,000
share options by the Company’s CEO, Kathrine Gamborg Andreassen. The exercised
share options were granted in May 2019 and have, following the completion of the
demerger in October 2019, a strike price of NOK 8.88 per share. The new shares
to be issued are subject to a 24 months lock-up period, subject to certain
exemptions, from the date the shares are received by the option holder.

Following the registration of the share capital increase with the Norwegian
Register of Business Enterprises (Nw. Foretaksregisteret), the Company’s share
capital will be NOK 11,315,994.90, divided into 15,291,885 shares, each with a
nominal value of NOK 0.74.

For further information, please contact:

Lars Hjarrand, CFO, Navamedic,
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a preferred, full-service provider of high-quality healthcare
products to hospitals and pharmacies. Navamedic meets the specific medical
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please visit
www.navamedic.com

This information is published pursuant to the continuing obligations of the Oslo
Stock Exchange.

Kilde